NCT00287547 - Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris | Biotech Hunter

Enrollment

144

Participants

Timeline

Start Date

March 31, 1997

Primary Completion Date

January 31, 1998

Study Completion Date

January 31, 1998

Conditions

Psoriasis Vulgaris

Interventions

DRUG

CTLA4Ig / Abatacept

Trial Locations (10)

Local Institution, San Diego

Local Institution, Chicago

Local Institution, Boston

Local Institution, Ann Arbor

Local Institution, New Brunswick

Local Institution, Portland

Local Institution, Philadelphia

Local Institution, Dallas

Local Institution, Salt Lake City

Local Institution, Burlington